Michalina Kolodziejczak

List of Publications by Year
in descending order

31 papers	1,878 citations	516215 16 h-index	476904 29 g-index
31 all docs	31 docs citations	31 times ranked	3787 citing authors

#	Article	IF	Citations
1	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 40-51.	2.0	357
2	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	3.8	339
3	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, The, 2015, 350, h1618-h1618.	3.0	279
4	Off-pump coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-pump coronary artery bypass grafting: Meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 60-77.e58.	0.4	165
5	Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease. Circulation: Heart Failure, 2017, 10, .	1.6	123
6	Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. International Journal of Cardiology, 2017, 227, 644-649.	0.8	91
7	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1753-1764.	0.7	80
8	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 201-213.	1.1	69
9	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome. Annals of Internal Medicine, 2016, 164, 600.	2.0	55
10	Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2018, 53, 495-504.	0.6	50
11	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. Annals of Internal Medicine, 2017, 167, 103.	2.0	43
12	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. Heart, 2015, 101, 1309-1317.	1.2	40
13	From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 44-53.	1.4	30
14	Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?. American Journal of Cardiovascular Drugs, 2014, 14, 79-87.	1.0	29
15	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. Mayo Clinic Proceedings, 2019, 94, 1457-1466.	1.4	19
16	Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature. Atherosclerosis, 2016, 247, 189-192.	0.4	16
17	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 47-54.	1.4	16
18	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2018, 258, 59-67.	0.8	14

#	Article	IF	Citations
19	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease â€“ A meta-analysis. International Journal of Cardiology, 2018, 269, 292-297.	0.8	14
20	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis, 2015, 114, 933-944.	1.8	11
21	30-day mortality reduction with miniaturized extracorporeal circulation as compared to conventional cardiopulmonary bypass for coronary revascularization. Meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 198, 63-65.	0.8	8
22	Procedural and 1-year outcomes following large vessel coronary artery perforation treated by covered stents implantation: Multicentre CRACK registry. PLoS ONE, 2021, 16, e0249698.	1.1	8
23	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2018, 16, 419-429.	0.6	7
24	Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy. American Journal of Cardiology, 2020, 125, 727-734.	0.7	3
25	Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysisâ€”Multicenter SVG PCI PROTECTA Study. Journal of Clinical Medicine, 2020, 9, 1198.	1.0	3
26	Clinical Outcomes following Large Vessel Coronary Artery Perforation Treated with Covered Stent Implantation: Comparison between Polytetrafluoroethylene- and Polyurethane-Covered Stents (CRACK-II Registry). Journal of Clinical Medicine, 2021, 10, 5441.	1.0	3
27	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. Annals of Internal Medicine, 2018, 168, 234.	2.0	2
28	Clinical Insights to Complete and Incomplete Surgical Revascularization in Atrial Fibrillation and Multivessel Coronary Disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
29	Things to avoid in meta-analysis. European Journal of Preventive Cardiology, 2013, 20, 513-513.	0.8	1
30	Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2017, 317, 439.	3.8	1
31	Drug-Eluting Stents and Coronary Artery Disease. , 2015, , 495-524.		0